Elan Pharmaceuticals, Inc.

University of California

Genentech, Inc.

Annexon, Inc.

Athena Neurosciences, Inc.

Biogen Idec Ma Inc.

Ted A Yednock

Jose William Saldanha

Steven D Rosen

Mary M Bendig

Mark S Singer

Olivier J Leger

Arnon Rosenthal

Laurence A Lasky

Michael W Leviten

Tarran Jones

Scott E Stachel

Sethu Sankaranarayanan

Andrei William Konradi

Michael A Pleiss

Christopher Michael Semko

Darren B Dressen

Stephen B Freedman

S Tarran Jones

Yasuyuki Imai

Julie Elizabeth Taylor

Francine S Farouz

Elizabeth Messersmith

Karen Krukowski

Stephen J Karlik

Susanna Rosi

The present disclosure relates generally to anti-C1q antibody Fab fragments and methods of using the same.

Anti-complement factor C1q Fab fragments and uses thereof

The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.

Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies

The application provides for methods and compositions for inhibiting demyelination, promoting remyelination and/or treating paralysis in a subject in need thereof. Preferably, such compositions include immunoglobulins (e.g., antibodies, antibody fragments, and recombinantly produced antibodies or fragments), polypeptides (e.g., soluble forms of the ligand proteins for integrins) and small molecules, which when administered in an effective amount inhibits demyelination and/or promotes remyelination in a patient. The compositions and methods described herein can also utilize other anti-inflammatory agents used to palliate conditions and diseases associated with demyelination.

Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents

Humanized anti-VLA4 immunoglobulins

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.

Humanized antibodies against leukocyte adhesion molecule VLA-4

The present invention provides novel assays for determining the ability of a test compound to inhibit intercellular adhesion mediated by a selectin receptor, such as the LHR. The assays involve contacting the test compound with the receptor and an isolated receptor-binding agent. The receptor-binding agent is a sulfated polysaccharide, a sulfated glycolipid, or a compound comprising the extracellular region of an endothelial cell surface glycoprotein. Also provided are compositions comprising a compound comprising the extracellular region of an endothelial cell surface protein, which is specifically recognized by lymphocyte homing receptors.

Assays for inhibitors of leukocyte adhesion

DNA isolates coding for the lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.

Lymphocyte homing receptors

DNA isolates coding for a lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.

DNA sequence encoding a functional domain of a lymphocyte homing receptor

Growing community of inventors

Fairfax, CA, United States of America

Ted A Yednock